Treatment Of Autoimmune Articles & Analysis: Older
11 news found
Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. However, the traditional antibody discovery process is labor-intensive, time-consuming, and costly. ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. ...
Her proven success spans a spectrum of life science companies, including GRAIL and Guardant Health where she developed and executed successful product launch strategies, and at Genentech where she led innovative autoimmune disease treatments through Phase I and II clinical trials with external collaborators. ...
He is currently President & CEO of Elex Biotech (Portland, OR), a company developing novel drugs for the treatment of arrhythmia and heart failure. Previously, Dr. Kawahara was Executive Vice President, Corporate Development for Oligos Etc. ...
Angany’s first two therapeutic products will be used in the treatment of allergy to peanuts and human allergy to cats. The two companies will share a booth at the 2021 Annual Scientific Meeting of the American College of Asthma Allergy and Immunology (ACAAI) to be held from November 4th to 8th in New Orleans. ...
“Cellular immunotherapies using regulatory T cells (Tregs) show tremendous promise for the treatment of autoimmune disease, transplant rejection, and graft-versus-host ...
“The relevance of NAbs as preventive or therapeutic treatments is all about metrics: higher neutralization potency means lower effective doses needed, and directly translates into the capacity to treat a higher number of patients (availability), at a lower cost (affordability), states Dr Gomord. ...
Additionally, long-term data on SOLIRIS for the treatment of neuromyelitis optica spectrum disorder (NMOSD) will be presented, including a disease model assessing the benefits of treatment and Phase 3 PREVENT clinical trial results evaluating SOLIRIS as a monotherapy. ...
Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of ...
The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option. ...
IBM is an autoimmune condition in which cytotoxic T cells attack muscle. Patients suffering from IBM have no reliably effective drug treatments currently available to them. This therapeutic will also be investigated for the treatment of PBC, an autoimmune condition in which pathogenic T cells attack bile ducts. While ...